Terms: = Breast cancer AND NSD1, FLJ44628, 64324, ENSG00000165671, Q96L73, FLJ22263, DKFZp666C163, ARA267, STO, SOTOS
29 results:
1. Treatment side affects exercising microvascular oxygenation response in active breast cancer survivors: A pilot study.
Cayot TE; Herbert B; Klika RJ
Clin Physiol Funct Imaging; 2023 Mar; 43(2):96-102. PubMed ID: 36376074
[TBL] [Abstract] [Full Text] [Related]
2. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With breast cancer in a Controlled Randomized Clinical Trial.
Johansson A; Dar H; van 't Veer LJ; Tobin NP; Perez-Tenorio G; Nordenskjöld A; Johansson U; Hartman J; Skoog L; Yau C; Benz CC; Esserman LJ; Stål O; Nordenskjöld B; Fornander T; Lindström LS
J Clin Oncol; 2022 Dec; 40(35):4071-4082. PubMed ID: 35862873
[TBL] [Abstract] [Full Text] [Related]
3. Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.
Opdam M; van der Noort V; Kleijn M; Glas A; Mandjes I; Kleiterp S; Hilbers FS; Kruger DT; Bins AD; de Jong PC; Schiphorst PPJBM; van Dalen T; Flameling B; Rietbroek RC; Beeker A; van den Heiligenberg SM; Bakker SD; Wymenga ANM; Oving IM; Bijlsma RM; van Diest PJ; Vermorken JB; van Tinteren H; Linn SC
Breast Cancer Res Treat; 2022 Jul; 194(2):265-278. PubMed ID: 35587322
[TBL] [Abstract] [Full Text] [Related]
4. Palbociclib regulates intracellular lipids in mammary tumor cells by secreting lipoprotein lipase.
Fujii T; Kamishikiryo J; Morita T
Pharmacol Rep; 2022 Jun; 74(3):503-512. PubMed ID: 35366749
[TBL] [Abstract] [Full Text] [Related]
5. Knockdown of nuclear receptor binding SET domain-containing protein 1 (nsd1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/β-catenin signaling pathway.
Chen Y; Li X; Xu J; Xiao H; Tang C; Liang W; Zhu X; Fang Y; Wang H; Shi J
Bioengineered; 2022 Feb; 13(2):3526-3536. PubMed ID: 35200072
[TBL] [Abstract] [Full Text] [Related]
6. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
Johansson A; Yu NY; Iftimi A; Tobin NP; van 't Veer L; Nordenskjöld B; Benz CC; Fornander T; Perez-Tenorio G; Stål O; Esserman LJ; Yau C; Lindström LS
Int J Cancer; 2022 Jun; 150(12):2072-2082. PubMed ID: 35179782
[TBL] [Abstract] [Full Text] [Related]
7. Nuclear receptor binding SET domain protein 1 promotes epithelial-mesenchymal transition in paclitaxel-resistant breast cancer cells via regulating nuclear factor kappa B and F-box and leucine-rich repeat protein 11.
Chen Y; Tang W; Zhu X; Zhang L; Zhu Y; Xiao H; Xu J; Fang Y; Li X; Tang C; Shi J
Bioengineered; 2021 Dec; 12(2):11506-11519. PubMed ID: 34905470
[TBL] [Abstract] [Full Text] [Related]
8. Early detection onset of flap failure using near infrared spectroscopy.
Sircan-Kucuksayan A; Ozkan O; Ozkan O; Kucuksayan E; Unal K; Canpolat M
J Plast Surg Hand Surg; 2022 Jun; 56(3):145-150. PubMed ID: 34323644
[TBL] [Abstract] [Full Text] [Related]
9. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative breast cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract] [Full Text] [Related]
10. Remote monitoring of head and neck free flaps using near infrared spectroscopic tissue oximetry.
Starr NC; Slade E; Gal TJ; Adekunle A; Bigler D; Cheung B; Wang D; Yeoh M; Liau J; Kejner A
Am J Otolaryngol; 2021; 42(1):102834. PubMed ID: 33229129
[TBL] [Abstract] [Full Text] [Related]
11. Identification of driver genes and key pathways of non-functional pituitary adenomas predicts the therapeutic effect of sto-609.
Wu B; Jiang S; Wang X; Zhong S; Bi Y; Yi D; Liu G; Hu F; Dou G; Chen Y; Wu Y; Dong J
PLoS One; 2020; 15(10):e0240230. PubMed ID: 33119597
[TBL] [Abstract] [Full Text] [Related]
12. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO sto 0217).
Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
[TBL] [Abstract] [Full Text] [Related]
13. Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors.
Hou Z; Min W; Zhang R; Niu A; Li Y; Cao L; Han J; Luo C; Yang P; Ding H
Bioorg Med Chem Lett; 2020 May; 30(9):127061. PubMed ID: 32173197
[TBL] [Abstract] [Full Text] [Related]
14. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
15. Systematic discovery of germline cancer predisposition genes through the identification of somatic second hits.
Park S; Supek F; Lehner B
Nat Commun; 2018 Jul; 9(1):2601. PubMed ID: 29973584
[TBL] [Abstract] [Full Text] [Related]
16. Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal breast cancer.
Lindström LS; Yau C; Czene K; Thompson CK; Hoadley KA; Van't Veer LJ; Balassanian R; Bishop JW; Carpenter PM; Chen YY; Datnow B; Hasteh F; Krings G; Lin F; Zhang Y; Nordenskjöld B; Stål O; Benz CC; Fornander T; Borowsky AD; Esserman LJ;
J Natl Cancer Inst; 2018 Jul; 110(7):726-733. PubMed ID: 29361175
[TBL] [Abstract] [Full Text] [Related]
17. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
van 't Veer LJ; Yau C; Yu NY; Benz CC; Nordenskjöld B; Fornander T; Stål O; Esserman LJ; Lindström LS
Breast Cancer Res Treat; 2017 Nov; 166(2):593-601. PubMed ID: 28776283
[TBL] [Abstract] [Full Text] [Related]
18. Use of Molecular Tools to Identify Patients With Indolent breast cancers With Ultralow Risk Over 2 Decades.
Esserman LJ; Yau C; Thompson CK; van 't Veer LJ; Borowsky AD; Hoadley KA; Tobin NP; Nordenskjöld B; Fornander T; Stål O; Benz CC; Lindström LS
JAMA Oncol; 2017 Nov; 3(11):1503-1510. PubMed ID: 28662222
[TBL] [Abstract] [Full Text] [Related]
19. Predicting Responses to Neoadjuvant Chemotherapy in breast cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging.
Tromberg BJ; Zhang Z; Leproux A; O'Sullivan TD; Cerussi AE; Carpenter PM; Mehta RS; Roblyer D; Yang W; Paulsen KD; Pogue BW; Jiang S; Kaufman PA; Yodh AG; Chung SH; Schnall M; Snyder BS; Hylton N; Boas DA; Carp SA; Isakoff SJ; Mankoff D;
Cancer Res; 2016 Oct; 76(20):5933-5944. PubMed ID: 27527559
[TBL] [Abstract] [Full Text] [Related]
20. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract] [Full Text] [Related]
[Next]
